Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The splicing factor RBM25 controls MYC activity in acute myeloid leukemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Shared heritability and functional enrichment across six solid cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Infant airway microbiota and topical immune perturbations in the origins of childhood asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Publisher Correction: Shared heritability and functional enrichment across six solid cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. ERG Controls B Cell Development by Promoting Igh V-to-DJ Recombination

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Functional consequences of structural variants on the 3D architecture of cancer genomes

    Publikation: Bog/antologi/afhandling/rapportPh.d.-afhandlingForskning

  3. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Cancer sequencing studies have implicated regulators of pre-mRNA splicing as important disease determinants in acute myeloid leukemia (AML), but the underlying mechanisms have remained elusive. We hypothesized that "non-mutated" splicing regulators may also play a role in AML biology and therefore conducted an in vivo shRNA screen in a mouse model of CEBPA mutant AML. This has led to the identification of the splicing regulator RBM25 as a novel tumor suppressor. In multiple human leukemic cell lines, knockdown of RBM25 promotes proliferation and decreases apoptosis. Mechanistically, we show that RBM25 controls the splicing of key genes, including those encoding the apoptotic regulator BCL-X and the MYC inhibitor BIN1. This mechanism is also operative in human AML patients where low RBM25 levels are associated with high MYC activity and poor outcome. Thus, we demonstrate that RBM25 acts as a regulator of MYC activity and sensitizes cells to increased MYC levels.

OriginalsprogEngelsk
TidsskriftNature Communications
Vol/bind10
Udgave nummer1
Sider (fra-til)172
ISSN2041-1723
DOI
StatusUdgivet - 11 jan. 2019

ID: 56215098